Abstract 1937
Background
Soft tissue sarcoma (STS) has been treated by achieving safe surgical margin rather than by using adjuvant radiotherapy (RT) in our country and 2-cm wide margin can be considered as adequate margin according to Kawaguchi’s criteria. We evaluated local recurrence (LR) and prognosis following resection of high-grade large STS using JOA surgical margin concept.
Methods
Treatment strategy: Surgical resection with at least 2cm-wide margin was attempted whenever possible. Marginal or 1cm-wide margin are acceptable when preserving neurovascular bundles. RT is conducted postoperatively for marginal or R1 margin. Chemotherapy is indicated for patients less than 60 years old with deep seated, high grade and large tumor. PATIENTS: Inclusion criteria are localized STS in the extremities or trunk, larger than 5cm, FNCLCC grade 2 or 3, limb sparing surgery, primary complete resection at our institution, and minimum 3 years of follow-up. We retrospectively analyzed 69 patients treated between 2007 and 2014.
Results
Median follow-up was 64 months. Median tumor size was 8.7cm. 6 patients underwent postoperative RT due to inadequate surgical margin. 21 (30%) patients received chemotherapy. There were 7 (10%) LR with average 14.5 months after surgery. Average size of tumor developing LR (14.8cm) was statistically larger than that without LR (9.8cm, p < 0.05). Only 1 of 9 patients developed LR after postoperative RT for inadequate resection. Distant metastasis was shown in 14 patients with average 20 months after surgery. There was no statistical difference of LR-free and overall survival between wide resection alone and inadequate resection with postoperative RT. Chemotherapy did not significantly affect overall survival.
Conclusions
In this series of high-grade large STS, resection alone with 2cm-wide margin led to good local control, which is identical to previous reports with surgery plus RT. Adjuvant RT should be given for resection with marginal margin or R1 margin of the resected specimen.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1844 - In Vivo Efficacy and Enhanced Tumor Accumulation of Liposomal Vinorelbine (TLC178) in Human Sarcoma Xenograft Mice Model
Presenter: Wan-ni Yu
Session: Poster Display session 1
Resources:
Abstract
2728 - MicroRNA expression and DNA methylation profiles do not distinguish between primary and recurrent well-differentiated liposarcoma
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
3197 - Genomic Alterations, Tumor Mutation Burden and Prognosis of Chinese Cardiac Sarcoma Patients
Presenter: Na Zhu
Session: Poster Display session 1
Resources:
Abstract
4214 - Evaluation of a peptide-conjugated alkylator melflufen in osteosarcoma preclinical models
Presenter: Konstantin Byrgazov
Session: Poster Display session 1
Resources:
Abstract
2654 - Expression analysis of NHEJ and HR genes in Ewing sarcomas: indications of DSB repair dysfunction
Presenter: Anastasios Kyriazoglou
Session: Poster Display session 1
Resources:
Abstract
4383 - Epidemiology of Synovial Sarcoma in EU28 countries
Presenter: Nedra Joseph
Session: Poster Display session 1
Resources:
Abstract
3757 - Influence of eribulin on proliferation, migration and invasion properties of leiomyosarcoma cell line models
Presenter: Marta Mendiola
Session: Poster Display session 1
Resources:
Abstract
1040 - EREMISS: Efficacy of regorafenib (REG) as maintenance therapy in non-adipocytic soft tissue sarcomas (STS) having received 1st-line doxorubicin-based chemotherapy (Doxo-CT)
Presenter: Nicolas Penel
Session: Poster Display session 1
Resources:
Abstract
1048 - A Phase 2 biomarker-driven study evaluating the clinical efficacy of an MDM2 inhibitor, milademetan, in patients with intimal sarcoma, a disease with a high unmet need
Presenter: Kan Yonemori
Session: Poster Display session 1
Resources:
Abstract
1511 - A pilot study of oral paclitaxel (ORAXOL) in subjects with cutaneous angiosarcomas (KX-ORAX-010)
Presenter: Herbert Loong
Session: Poster Display session 1
Resources:
Abstract